A Study Of Peritoneal-Lavage Methylated DNA Markers In Gastric Cancer

Overview

About this study

The purpose of this study is to establish a biobank of samples (peritoneal fluid and blood) to support the development of non-invasive tests for the detection and recurrence of gastric cancer.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age >18 years.

  • Patient has a histological or suspected diagnosis of primary gastric cancer.

  • Scheduled for staging laparoscopy.

Exclusion Criteria:

  • Patient has recurrence of gastric cancer.

  • Patient has a history of another primary cancer within the past 5 years (excluding non-melanoma skin cancer)

  • Patient has a history of organ transplantation.

  • Patient has active infections or intra-abdominal sepsis.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 9/25/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Contact us for the latest status

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions